PubMed ID:
25887357
Public Release Type:
Journal
Publication Year: 2015
Affiliation: Department of Medicine, University of California, San Diego, La Jolla, CA Divisions of Gastroenterology and Epidemiology, University of California, San Diego, La Jolla, CA roloomba@ucsd.edu.
DOI:
https://doi.org/10.2337/dc14-1239
Authors:
Kleiner D,
Bazick J,
Brunt EM,
Donithan M,
Doo E,
Lavine J,
Loomba R,
Neuschwander-Tetri BA,
Tonascia J,
Wilson L
Studies:
Nonalcoholic Steatohepatitis Clinical Research Network
Approximately 18 million people in the U.S. have coexisting type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). It is not known who among these patients has nonalcoholic steatohepatitis (NASH) with advanced fibrosis. Therefore, we aimed to determine factors that are associated with both NASH and advanced fibrosis in patients with diabetes and NAFLD in order to identify who should be prioritized for referral to a hepatologist for further diagnostic evaluation and treatment.